Dicot has received approval to start phase 1 clinical trial
Press release: Uppsala, August 15, 2023. Dicot announces that the Swedish Medical Products Agency has granted permission to start clinical phase 1 trial with the drug candidate LIB-01. It is a placebo-controlled trial with primary objective to evaluate the safety profile in humans.Dicot's first-in-human study of the potency drug candidate LIB-01 has now received permission to start from the Swedish Medical Products Agency. Approval from the Ethics Review Authority has also been obtained and other preparations are complete. Screening of participants and dosing of the first dose group will